Plus Therapeutics Inc. (NASDAQ:PSTV) jumped 60% in premarket trading Thursday following news of a national agreement with ...

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with ...

The test supports rapid diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

Investing.com -- Plus Therapeutics Inc (NASDAQ:PSTV) stock surged 60% in premarket trading Thursday after the company ...

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), announced that it has signed a national agreement with UnitedHealthcare ...

Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus ...